On June 22nd, the A-share and H-share innovative drug sectors faced renewed pressure. The Huabao Pharmaceutical ETF (SHSE: 562050), which is heavily weighted in A-share innovative drug stocks, and the Huabao Hong Kong Stock Connect Innovative Drug ETF (SHSE: 520880), which is fully invested in Hong Kong-listed pharma, both hit new historical lows.
The A-share pharmaceutical sector opened lower and continued to decline. The Huabao Pharmaceutical ETF (SHSE: 562050), the sole on-exchange ETF tracking the pharmaceutical sector, fell over 3% intraday, with its constituent stocks broadly declining, including a 20% drop for Bioray Pharmaceutical.
The Hong Kong Stock Connect innovative drug segment also experienced a one-sided downward movement. The Huabao Hong Kong Stock Connect Innovative Drug ETF (SHSE: 520880), which invests 100% in innovative drug R&D companies, also fell over 3% intraday. All 50 of its constituent stocks were in negative territory, with heavyweight stock Akeso, Inc. plunging nearly 8% to a near one-year low.
Notably, since the second quarter, both the A-share and H-share pharmaceutical sectors have witnessed a wave of share buybacks and insider purchases. From April 1st to June 18th, dozens of listed pharmaceutical companies in the A-share and H-share markets announced share purchase plans. Some drugmakers announced buyback programs as many as 40 times, with the cumulative repurchase amounts and share volumes continuously increasing. Industry capital is sending a clear signal to the market with real money, indicating that current price levels possess significant investment value.
Leading innovative drug companies are at the forefront of this buyback wave. Sino Biopharmaceutical Limited announced a plan to repurchase up to HK$2 billion in shares over the next 12 months, explicitly stating that "the company's value is severely undervalued." Following the announcement of key clinical data, Akeso, Inc. swiftly proposed a HK$200 million share repurchase plan, with management also planning to use HK$50 million of their own funds to increase their holdings, clearly stating that "the current trading price of the shares does not reflect their intrinsic value."
Historical experience suggests that when companies themselves become their own most steadfast bulls, and when buyback announcements shift from being "occasional" to "frequent," the characteristics of a sector bottoming out become increasingly clear.
For investors looking to acquire core innovative drug assets at lower prices, consider these two key investment tools:
For a pure play on innovative drugs, the Huabao Hong Kong Stock Connect Innovative Drug ETF (SHSE: 520880) offers 100% exposure to innovative drug R&D companies. Its top ten holdings account for over 70% of the portfolio, highlighting its focus on industry leaders. Its underlying assets are Hong Kong-listed stocks, offering high volatility and T+0 trading.
For investors seeking to reduce volatility, the unique Huabao Pharmaceutical ETF (SHSE: 562050) provides an exclusive allocation of "75% innovative drugs + 25% traditional Chinese medicine." This rare offering in the market combines the high growth potential of innovative drugs with the high dividend characteristics of traditional Chinese medicine stocks.
Data is sourced from the Shanghai, Shenzhen, and Hong Kong stock exchanges, as well as China Securities Index Co., Ltd. and Hang Seng Indexes Company.
Note: ETF funds do not charge sales service fees. When subscribing for or redeeming fund shares, subscription/redemption agents may charge a commission not exceeding 0.5%, which includes relevant fees charged by stock exchanges and registration institutions. Detailed fund fee structures are available in the respective fund legal documents.
Risk Disclosure: The index constituents mentioned are for illustrative purposes only. Descriptions of individual stocks do not constitute investment advice in any form, nor do they represent the holdings or trading动向 of any fund managed by the fund manager. The fund manager assesses the risk rating of the Huabao Pharmaceutical ETF and its feeder funds as R3 (Medium Risk), suitable for Balanced (C3) and above investors. The risk rating for the Huabao Hong Kong Stock Connect Innovative Drug ETF and its feeder funds is assessed as R4 (Medium-High Risk), suitable for Aggressive (C4) and above investors. Any information appearing in this article (including but not limited to individual stocks, commentary, forecasts, charts, indicators, theories, and any form of expression) is for reference only. Investors are responsible for their own investment decisions. Furthermore, any views, analysis, or forecasts in this article do not constitute investment advice of any kind to readers, and no responsibility is taken for any direct or indirect losses arising from the use of this content. The performance of other funds managed by the fund manager does not guarantee the performance of these funds. Past performance of a fund is not indicative of its future results. Fund investment carries risks.
Comments